Related Experiment Video
Updated: Jun 29, 2025
06:02
Posterior Approach for Debridement of the Psoas Abscess
Published on: March 2, 2020
11.1K
Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for
Shunsuke Owa1, Takeshi Sasaki1, Ryota Ikadai1
1Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.
International Journal of Clinical Oncology
|April 8, 2024
Summary
Low psoas muscle index predicts worse outcomes in metastatic castration-sensitive prostate cancer. This finding highlights the importance of muscle mass assessment for predicting survival in these patients.
Area of Science:
- Oncology
- Radiology
- Urology
Background:
- Low skeletal muscle mass is linked to poor oncological outcomes in prostate cancer.
- The impact of psoas muscle parameters on hormone-treated metastatic castration-sensitive prostate cancer outcomes is not well understood.
Purpose of the Study:
- To investigate the association between psoas muscle parameters and oncological outcomes in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy.
Main Methods:
- Retrospective review of 121 patients with N1 and/or M1 metastatic castration-sensitive prostate cancer treated with androgen deprivation therapy.
- Evaluation of psoas muscle index and Hounsfield units using non-contrast computed tomography before treatment.
- Analysis of oncological outcomes including castration-resistant prostate cancer-free survival and overall survival.
Main Results:
- Multivariate analysis revealed that the Gleason score, clinical N-stage, and psoas muscle index were significant predictors.
- A lower psoas muscle index (median cutoff: 3.044 cm²/m²) was associated with poorer outcomes.
Conclusions:
- Pretreatment psoas muscle index is an independent predictor of unfavorable castration-resistant prostate cancer-free survival and overall survival.
- Psoas muscle index is a valuable prognostic biomarker for patients with metastatic castration-sensitive prostate cancer.
